Romosozumab-aqqg and Osteonecrosis of the jaw
Result of checking the interaction of drug Romosozumab-aqqg and disease Osteonecrosis of the jaw for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Osteonecrosis of the jaw (ONJ), has been reported in patients receiving romosozumab. A routine oral examination should be performed prior to initiation of treatment. Risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, preexisting dental disease or infection, anemia, and coagulopathy, and concomitant use of other drugs associated with ONJ (e.g., chemotherapy, bisphosphonates). Patients requiring invasive dental procedures, require clinical judgment of the treating physician and/or oral surgeon to guide the management plan based on benefit-risk assessment. Patients who are suspected of having or who develop ONJ while on romosozumab treatment, should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of treatment should be considered based on benefit-risk assessment.
Generic Name: romosozumab
Brand Name: Evenity
Synonyms: Romosozumab